149. Cancer Res. 2018 Apr 15;78(8):1948-1957. doi: 10.1158/0008-5472.CAN-17-2078. Epub2018 Feb 5.S-Nitrosylation of cIAP1 Switches Cancer Cell Fate from TNFα/TNFR1-Mediated Cell Survival to Cell Death.Romagny S(1)(2), Bouaouiche S(1)(2), Lucchi G(3), Ducoroy P(3), Bertoldo JB(4),Terenzi H(4), Bettaieb A(1)(2), Plenchette S(5)(2).Author information: (1)EPHE, PSL Research University, Paris, France.(2)LIIC, EA7269, Université de Bourgogne Franche-Comté, Dijon, France.(3)Université de Bourgogne Franche-Comté, Clinical and Innovation ProteomicPlatform, Dijon, France.(4)Centro de Biologia Molecular Estrutural-Universidade Federal de SantaCatarina, Campus Trindade, Florianópolis, Santa Catarina, Brasil.(5)EPHE, PSL Research University, Paris, France.Stephanie.plenchette@u-bourgogne.fr.TNFα is a prominent proinflammatory cytokine and a critical mediator for thedevelopment of many types of cancer such as breast, colon, prostate, cervical,skin, liver, and chronic lymphocytic leukemia. Binding of TNFα to TNFR1 can lead to divergent signaling pathways promoting predominantly NF-κB activation but alsocell death. We report here that the nitric oxide (NO) donor glyceryl trinitrate(GTN) converts TNFα, generated from immune cells or cancer cells stimulated bychemotherapy, into a prodeath mediator in colon and mammary cancer cells.GTN-mediated S-nitrosylation of cIAP1 on cysteines 571 and 574 inhibited its E3ubiquitin ligase activity, which in turn reduced Lys63-linked ubiquitination ofRIP1 and initiated assembly of a death complex. These findings provide insightsinto how NO can harness advantageous aspects of inflammation in cancer andprovide new therapeutic strategies.Significance: Combination of an NO donor with chemotherapeutic drug-induced TNFα represents a potentially valuable anticancerstrategy. Cancer Res; 78(8); 1948-57. ©2018 AACR.©2018 American Association for Cancer Research.DOI: 10.1158/0008-5472.CAN-17-2078 PMID: 29431638 